The ASH 2020 62nd Annual Meeting and Symposium brought a whirlwind of activity and CLL Society enjoyed its virtual front row seat and well-earned access to the top CLL researchers and presenters.
CLL Society has accumulated months of Weekly Alert, Tribune, and social media-worthy news and research to share with you and we will help you sort through all that’s new in CLL treatment. Stay tuned!
Highlights From ASH 2020 Day 3 brought news on the effectiveness of CD19-CAR T Cells in Richter’s Transformation, 2 CAR-T oral presentations concerning liso-cel (Lisocabtagene Maraleucel/ with and without ibrutinib), LOXO-305, Umbralisib + Ublituximab, as well as Real-World Prognostic Biomarker Testing, which lends supportive data to the importance of CLL Society’s Test Before Treat™ campaign. Learn more here.
Highlights From ASH 2020 Day 4 Updates / Wrap-Up
Dec. 8 was the 4th and final day of ASH 2020, the American Society of Hematology Annual meeting and Exposition. Less fun! No hugs. But we are leaving with a lot of treats and the promise of much more to come. Read Dr. Koffman’s long list of take-aways here.
Celebrating 10 Years of ASH!
As ASH comes to a close, we close our 10 Years of Covering ASH (and all the other major hematology conferences) Celebration. CLL Society brings you the most important, breaking CLL research news in patient-friendly terms. Support the ongoing work of the CLL Society. Please donate today. Thank you!
ASH 2019 Conference Coverage
Science moves fast! Follow the evolution of the development of BTKis! At ASH 2019 Dr. John Allan discussed the advantages of the next generation BTKi vecabrutinib that binds differently and may overcome the most common reason we develop resistance to the first generation BTKis ibrutinib and acalabrutinib. While vecabrutinib is no longer being commercially developed, LOXO 305 and Arq 531 (or MK-1026, as it is now known) are reversibly binding BTK inhibitors that are currently in clinical trials. Learn more here.
MRD Knowledge – We Want to Hear From You!
Help us learn about your knowledge, attitude, and preference about MRD (measurable residual disease or minimal residual disease) and limited duration (also known as fixed duration) therapies. If you haven’t done so already, please complete our MRD / LD Survey Here!
CLL Society Has You Covered for MRD Information
We need to know when to start treatment, how well the treatment is working, and when we might be able to stop treatment. Many major advances have been made in measuring our amount of disease, now giving us the ability to look for minimal amounts of residual disease (MRD) down to being able to detect one cancer cell among a million normal cells. Learn more here.
Facebook Live Event with Brian Koffman
2 Physicians with CLL! Join us for a CLL Society/ Facebook Live event Wednesday Dec. 16. Watch Dr. Brian Koffman and a fellow physician, both with CLL, share stories of the impact of their diagnosis and the strategies they implemented for increasing their knowledge about CLL and arranging proper care.
No registration needed, join us here on Wednesday, December 16 at 4 PM EST!
As we draw closer to the holiday season, we urge you to continue vigilance in protecting yourselves from exposure to COVID-19.
Please support the CLL Society, the only CLL-specific, physician-curated public charity dedicated to meeting the unmet needs of CLL patients and their caregivers which holds the GuideStar Platinum Seal of Transparency.
Thank you and stay safe!
We are all in this together.
Co-Founder & Communications Director
CLL Society Support Group Meetings Coming Up!
CLL Society Support Group meetings have moved to a virtual platform for most locations due to the threat of coronavirus. Support group members will receive an invitation to register for the meeting from the support group facilitator. If you are new to the group, please contact the RSVP email for the Support Group in your region. Once it is safe again, we will resume in-person meetings.
Visit the individual event listings on our website for the most up-to-date information on all CLL Society Support Group meetings.